Search Results - "Boer, Rudolf A."

Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology by Seferovic, Petar M., Ponikowski, Piotr, Anker, Stefan D., Bauersachs, Johann, Chioncel, Ovidiu, Cleland, John G.F., Boer, Rudolf A., Drexel, Heinz, Ben Gal, Tuvia, Hill, Loreena, Jaarsma, Tiny, Jankowska, Ewa A., Anker, Markus S., Lainscak, Mitja, Lewis, Basil S., McDonagh, Theresa, Metra, Marco, Milicic, Davor, Mullens, Wilfried, Piepoli, Massimo F., Rosano, Giuseppe, Ruschitzka, Frank, Volterrani, Maurizio, Voors, Adriaan A., Filippatos, Gerasimos, Coats, Andrew J.S.

“…The European Society of Cardiology (ESC) has published a series of guidelines on heart failure (HF) over the last 25 years, most recently in 2016. Given the…”
Get full text

Cancer and heart disease: associations and relations by Boer, Rudolf A., Meijers, Wouter C., Meer, Peter, Veldhuisen, Dirk J.

“…Emerging evidence supports that cancer incidence is increased in patients with cardiovascular (CV) disease and heart failure (HF), and patients with HF…”
Get full text

Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer by Karlstaedt, Anja, Moslehi, Javid, de Boer, Rudolf A.

“…Cardiovascular disease and cancer are the two leading causes of morbidity and mortality in the world. The emerging field of cardio-oncology has revealed that…”
Get full text

Common risk factors for heart failure and cancer by Meijers, Wouter C, de Boer, Rudolf A

“…Abstract Cardiovascular (CV) disease and cancer are the leading causes of death.1,2 Over the last decades, it has been appreciated that both CV disease and…”
Get full text

Connecting epicardial adipose tissue and heart failure with preserved ejection fraction: mechanisms, management and modern perspectives by Woerden, Gijs, Veldhuisen, Dirk J., Westenbrink, B. Daan, Boer, Rudolf A., Rienstra, Michiel, Gorter, Thomas M.

“…Obesity is very common in patients with heart failure with preserved ejection fraction (HFpEF) and it has been suggested that obesity plays an important role…”
Get full text

Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio‐Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio‐Oncology Society by Lyon, Alexander R., Dent, Susan, Stanway, Susannah, Earl, Helena, Brezden‐Masley, Christine, Cohen‐Solal, Alain, Tocchetti, Carlo G., Moslehi, Javid J., Groarke, John D., Bergler‐Klein, Jutta, Khoo, Vincent, Tan, Li Ling, Anker, Markus S., Haehling, Stephan, Maack, Christoph, Pudil, Radek, Barac, Ana, Thavendiranathan, Paaladinesh, Ky, Bonnie, Neilan, Tomas G., Belenkov, Yury, Rosen, Stuart D., Iakobishvili, Zaza, Sverdlov, Aaron L., Hajjar, Ludhmila A., Macedo, Ariane V.S., Manisty, Charlotte, Ciardiello, Fortunato, Farmakis, Dimitrios, Boer, Rudolf A., Skouri, Hadi, Suter, Thomas M., Cardinale, Daniela, Witteles, Ronald M., Fradley, Michael G., Herrmann, Joerg, Cornell, Robert F., Wechelaker, Ashutosh, Mauro, Michael J., Milojkovic, Dragana, Lavallade, Hugues, Ruschitzka, Frank, Coats, Andrew J.S., Seferovic, Petar M., Chioncel, Ovidiu, Thum, Thomas, Bauersachs, Johann, Andres, M. Sol, Wright, David J., López‐Fernández, Teresa, Plummer, Chris, Lenihan, Daniel

“…This position statement from the Heart Failure Association of the European Society of Cardiology Cardio‐Oncology Study Group in collaboration with the…”
Get full text

Advancing the fight against fibrosis in patients with heart failure: The contribution of sodium–glucose cotransporter 2 inhibition by Boer, Rudolf A., Díez, Javier

Get full text

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial by Solomon, Scott D., Boer, Rudolf A., DeMets, David, Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Lam, Carolyn S.P., Martinez, Felipe, Shah, Sanjiv J., Lindholm, Daniel, Wilderäng, Ulrica, Öhrn, Fredrik, Claggett, Brian, Langkilde, Anna Maria, Petersson, Magnus, McMurray, John J.V.

“…Aims Sodium–glucose co‐transporter 2 (SGLT2) inhibitors, originally developed as glucose‐lowering agents, have been shown to reduce heart failure…”
Get full text

Sex‐related differences in contemporary biomarkers for heart failure: a review by Suthahar, Navin, Meems, Laura M.G., Ho, Jennifer E., Boer, Rudolf A.

“…ABSTRACT The use of circulating biomarkers for heart failure (HF) is engrained in contemporary cardiovascular practice and provides objective information about…”
Get full text

Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy by Bauersachs, Johann, König, Tobias, Meer, Peter, Petrie, Mark C., Hilfiker‐Kleiner, Denise, Mbakwem, Amam, Hamdan, Righab, Jackson, Alice M., Forsyth, Paul, Boer, Rudolf A., Mueller, Christian, Lyon, Alexander R., Lund, Lars H., Piepoli, Massimo F., Heymans, Stephane, Chioncel, Ovidiu, Anker, Stefan D., Ponikowski, Piotr, Seferovic, Petar M., Johnson, Mark R., Mebazaa, Alexandre, Sliwa, Karen

“…Peripartum cardiomyopathy (PPCM) is a potentially life‐threatening condition typically presenting as heart failure with reduced ejection fraction (HFrEF) in…”
Get full text

How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) by Pieske, Burkert, Tschöpe, Carsten, Boer, Rudolf A., Fraser, Alan G., Anker, Stefan D., Donal, Erwan, Edelmann, Frank, Fu, Michael, Guazzi, Marco, Lam, Carolyn S.P., Lancellotti, Patrizio, Melenovsky, Vojtech, Morris, Daniel A., Nagel, Eike, Pieske-Kraigher, Elisabeth, Ponikowski, Piotr, Solomon, Scott D., Vasan, Ramachandran S., Rutten, Frans H., Voors, Adriaan A., Ruschitzka, Frank, Paulus, Walter J., Seferovic, Petar, Filippatos, Gerasimos

“…Making a firm diagnosis of chronic heart failure with preserved ejection fraction (HFpEF) remains a challenge. We recommend a new stepwise diagnostic process,…”
Get full text

Kidney and heart failure outcomes associated with SGLT2 inhibitor use by van der Aart-van der Beek, Annemarie B., de Boer, Rudolf A., Heerspink, Hiddo J. L.

“…Chronic kidney disease (CKD) and heart failure affect many people worldwide. Despite the availability of pharmacological treatments, both diseases remain…”
Get full text

Effects of the dual sodium–glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure by Boer, Rudolf A., Núñez, Julio, Kozlovski, Plamen, Wang, Yi, Proot, Pieter, Keefe, Deborah

“…Aims Explore the efficacy, safety and tolerability of the dual sodium–glucose cotransporter (SGLT) 1 and 2 inhibitor, licogliflozin in patients with type‐2…”
Get full text

Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC) by Meijers, Wouter C., Bayes‐Genis, Antoni, Mebazaa, Alexandre, Bauersachs, Johann, Cleland, John G.F., Coats, Andrew J.S., Januzzi, James L., Maisel, Alan S., McDonald, Kenneth, Mueller, Thomas, Richards, A. Mark, Seferovic, Petar, Mueller, Christian, Boer, Rudolf A.

“…New biomarkers are being evaluated for their ability to advance the management of patients with heart failure. Despite a large pool of interesting candidate…”
Get full text

Galectin-3: a novel mediator of heart failure development and progression by de Boer, Rudolf A., Voors, Adriaan A., Muntendam, Pieter, van Gilst, Wiek H., van Veldhuisen, Dirk J.

“…Galectins are a family of soluble β-galactoside-binding lectins that play many important regulatory roles in inflammation, immunity, and cancer. Recently, a…”
Get full text

Ketone bodies for the failing heart: fuels that can fix the engine? by Yurista, Salva R., Nguyen, Christopher T., Rosenzweig, Anthony, de Boer, Rudolf A., Westenbrink, B. Daan

“…Accumulating evidence suggests that the failing heart reverts energy metabolism toward increased utilization of ketone bodies. Despite many discrepancies in…”
Get full text

Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high‐risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology by Harjola, Veli‐Pekka, Parissis, John, Bauersachs, Johann, Brunner‐La Rocca, Hans‐Peter, Bueno, Hector, Čelutkienė, Jelena, Chioncel, Ovidiu, Coats, Andrew J.S., Collins, Sean P., Boer, Rudolf A., Filippatos, Gerasimos, Gayat, Etienne, Hill, Loreena, Laine, Mika, Lassus, Johan, Lommi, Jyri, Masip, Josep, Mebazaa, Alexandre, Metra, Marco, Miró, Òscar, Mortara, Andrea, Mueller, Christian, Mullens, Wilfried, Peacock, W. Frank, Pentikäinen, Markku, Piepoli, Massimo F., Polyzogopoulou, Effie, Rudiger, Alain, Ruschitzka, Frank, Seferovic, Petar, Sionis, Alessandro, Teerlink, John R., Thum, Thomas, Varpula, Marjut, Weinstein, Jean Marc, Yilmaz, Mehmet B.

“…Acute coronary syndrome is a precipitant of acute heart failure in a substantial proportion of cases, and the presence of both conditions is associated with a…”
Get full text

Reverse Cardio-Oncology: Cancer Development in Patients With Cardiovascular Disease by Aboumsallem, Joseph Pierre, Moslehi, Javid, de Boer, Rudolf A

Get full text

Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction by Kosiborod, Mikhail N., Bhatt, Ankeet S., Claggett, Brian L., Vaduganathan, Muthiah, Kulac, Ian J., Lam, Carolyn S.P., Hernandez, Adrian F., Martinez, Felipe A., Inzucchi, Silvio E., Shah, Sanjiv J., de Boer, Rudolf A., Jhund, Pardeep S., Desai, Akshay S., Fang, James C., Han, Yaling, Comin-Colet, Josep, Vardeny, Orly, Lindholm, Daniel, Wilderäng, Ulrica, Bengtsson, Olof, McMurray, John J.V., Solomon, Scott D.

“…Patients with heart failure with mildly reduced ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) experience a high burden…”
Get full text

Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology by Seferović, Petar M., Fragasso, Gabriele, Petrie, Mark, Mullens, Wilfried, Ferrari, Roberto, Thum, Thomas, Bauersachs, Johann, Anker, Stefan D., Ray, Robin, Çavuşoğlu, Yuksel, Polovina, Marija, Metra, Marco, Ambrosio, Giuseppe, Prasad, Krishna, Seferović, Jelena, Jhund, Pardeep S., Dattilo, Giuseppe, Čelutkiene, Jelena, Piepoli, Massimo, Moura, Brenda, Chioncel, Ovidiu, Ben Gal, Tuvia, Heymans, Stefan, Boer, Rudolf A., Jaarsma, Tiny, Hill, Loreena, Lopatin, Yuri, Lyon, Alexander R., Ponikowski, Piotr, Lainščak, Mitja, Jankowska, Ewa, Mueller, Christian, Cosentino, Francesco, Lund, Lars, Filippatos, Gerasimos S., Ruschitzka, Frank, Coats, Andrew J.S., Rosano, Giuseppe M.C.

“…Heart failure (HF) is common and associated with a poor prognosis, despite advances in treatment. Over the last decade cardiovascular outcome trials with…”
Get full text